Magen E, Viskoper R J
WHO Collaborative Center for Prevention of Cardiovascular Diseases and Hypertension, Department of Medicine B, Barzilai Medical Center, Ashkelon, Israel.
Isr Med Assoc J. 2000 Dec;2(12):929-34.
Renin-angiotensin-aldosterone systems play a critical role in the development and progression of cardiovascular diseases, and inhibitors of angiotensin-converting enzyme have proven effective for the treatment of these diseases. Since angiotensin II receptor antagonists can inhibit the effects of angiotensin II via ACE-independent pathways, e.g., chymase, they were considered to be more effective than ACEIs. On the other hand, ACE inhibitors can increase bradykinin, and thus, nitric oxide, which may cause potent cardioprotection, inhibition of smooth muscle proliferation and attenuation of inflammation mechanisms. It appears that angiotensin II receptor antagonists and ACEIs may mediate cardioprotection in different ways. This is the rationale to explore the possibility of a combined administration of both drugs for the treatment of chronic heart failure and other cardiovascular pathology. In this review we try to analyze the role of ACE, kinins and chymase inhibition in the pathophysiology and treatment of cardiovascular diseases.
肾素-血管紧张素-醛固酮系统在心血管疾病的发生和发展中起关键作用,血管紧张素转换酶抑制剂已被证明对这些疾病的治疗有效。由于血管紧张素II受体拮抗剂可通过不依赖ACE的途径(如糜酶)抑制血管紧张素II的作用,因此它们被认为比ACEI更有效。另一方面,ACE抑制剂可增加缓激肽,进而增加一氧化氮,这可能会产生强大的心脏保护作用、抑制平滑肌增殖并减轻炎症机制。血管紧张素II受体拮抗剂和ACEI似乎可能以不同方式介导心脏保护作用。这就是探索联合使用这两种药物治疗慢性心力衰竭和其他心血管疾病可能性的理论依据。在本综述中,我们试图分析ACE、激肽和糜酶抑制在心血管疾病病理生理学和治疗中的作用。